Naurex to Present at UBS Global Healthcare Conference

EVANSTON, Ill., May 15, 2014 /PRNewswire/ -- Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, PhD, will present at the UBS Global Healthcare Conference on Monday, May 19, 2014 at 1:00 p.m. EDT. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.

Last week Naurex reported positive top-line Phase 2b results for GLYX-13 and the advancement of NRX-1074 into a Phase 2 depression study. The company also announced that existing shareholders invested an additional $25 million in the company.

The UBS Global Healthcare Conference will be held May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City.  For more information, visit www.ubs.com/global/en/investment-bank/key-investor-conferences/global.html.

About Naurex Inc.
Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the central nervous system (CNS). The company's first-generation compound, GLYX-13, is in development as adjunctive therapy for patients with difficult-to-treat depression. GLYX-13 has shown rapid-acting and robust antidepressant activity in Phase 2 clinical studies and has been well tolerated with none of the psychotomimetic side effects that limit other drugs and mechanisms targeting the NMDA receptor. Naurex's second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development for the treatment of major depressive disorder. These lead programs stem from the company's proprietary platform for discovering compounds that work through a novel mechanism, selectively modulating subtypes of the NMDA receptor to affect pathways involved with neuroplasticity. This mechanism has therapeutic potential in a number of CNS indications with high unmet medical needs. For more information, visit www.naurex.com.

SOURCE Naurex Inc.